BioKangtai(SZ:300601)2022-12-03 09:06Group 1: Industry Overview - The vaccine industry is gradually recovering, with the national regulatory mechanisms for the vaccine industry yet to be publicly announced [2] - Future national regulations will strengthen oversight and raise industry entry barriers, favoring companies with high product quality and standardized management [3] Group 2: Product Development - The company has withdrawn the application for the freeze-dried human rabies vaccine (MRC-5) to concentrate resources on other key vaccine developments, as the development progress of the alternative vaccine is similar [3] - The freeze-dried human rabies vaccine (human diploid cells) has completed Phase III clinical trials and is in the summary stage, with production application expected soon [3] Group 3: Clinical Trials and Research - The 13-valent pneumonia vaccine has completed Phase III clinical trials, with results expected by the end of the year [4] - The Sabin strain inactivated polio vaccine (Vero cells) is currently in Phase III clinical research, with the workshop under construction [5] Group 4: Future Plans and Production - The new production base in Guangming will primarily produce genetic engineering vaccines and viral vaccines, including hepatitis B, EV71, hepatitis A, and rotavirus vaccines [5] - The original site in Nanshan will be demolished and rebuilt as a bio-industry research and headquarters center, aiming to create a collaborative platform for industry, academia, and research [4] Group 5: Shareholder Actions - The controlling shareholder's increase plan will be implemented within 12 months from the announcement date, with timely information disclosure to follow [5]